华泰柏瑞中证创新药产业ETF(517120)利润分配表
| |
2025-06-30 |
2024-12-31 |
2024-06-30 |
2023-12-31 |
| 收入 |
71,653,463.88 |
-51,380,097.48 |
-105,718,527.02 |
-44,778,306.32 |
| 利息合计 |
16,042.96 |
38,728.09 |
21,883.56 |
54,375.67 |
| 其中：存款利息收入 |
16,042.96 |
38,728.09 |
21,883.56 |
54,375.67 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-29,929,181.79 |
-43,244,779.00 |
-32,283,153.45 |
-39,674,966.47 |
| 其中：股票投资收益 |
-31,587,598.69 |
-47,394,989.60 |
-34,792,067.09 |
-42,840,130.65 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
- |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
1,658,416.90 |
4,150,210.60 |
2,508,913.64 |
3,165,164.18 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
101,728,617.89 |
-8,310,749.55 |
-73,594,214.56 |
-5,476,898.58 |
| 其他收入 |
-162,015.18 |
136,702.98 |
136,957.43 |
319,183.06 |
| 费用 |
1,051,580.97 |
2,192,377.02 |
1,098,980.33 |
2,602,012.10 |
| 管理人报酬 |
731,949.15 |
1,545,112.92 |
778,209.48 |
1,871,851.76 |
| 基金托管费 |
146,389.79 |
309,022.59 |
155,641.90 |
374,370.43 |
| 销售服务费 |
- |
- |
- |
- |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中：卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
173,242.03 |
338,241.51 |
165,128.95 |
355,789.91 |
| 利润总额 |
70,601,882.91 |
-53,572,474.50 |
-106,817,507.35 |
-47,380,318.42 |
微信公众号
证券之星APP
基本资料
